Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

This publication has 24 references indexed in Scilit:

• European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma
  Seminars in Oncology, 2002
• Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials
  Journal of Clinical Oncology, 2002
• Interferon alfa-2a for melanoma metastases
  The Lancet, 2002
• Quality-of-Life-Adjusted Survival Analysis of High-Dose Adjuvant Interferon Alfa-2b for High-Risk Melanoma Patients Using Intergroup Clinical Trial Data
  Journal of Clinical Oncology, 2002
• Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
  The Lancet, 2001
• Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients
  British Journal of Haematology, 2001
• Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases
  The Lancet, 1998
• Results of adjuvant interferon study In WHO melanoma programme
  The Lancet, 1994
• Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards
  JAMA, 1992
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
  The Lancet, 1992